LICL – Publications

Discover the LICL main publications :

• Vignot S*, Drouet Y*, Di Meglio A, Martin AL, Gaudin C, Bertaut A, Fournier M, Jacot W, Cheymol C, Kieffer A, Tarpin C, Lerebours F, Caux C, Boyault S, Ménétrier-Caux C ^$, Olivier Trédan O ^$ (* co-first, ^$ co-last).
  Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.
  Breast Cancer Res (2026) in press.
• I. Ray-Coquard, M.C. Kaminsky-Forrett, R. Ohkuma, A. de Montfort, F. Joly, I. Treilleux, S. Ghamry-Barrin, D. Bello-Roufai, P. Saintigny, A. Angelergues, L. Michon, A.C. Hardy-Bessard, V. Attignon, J. Auclair, G. Chemin, A. Lainé, H. Péré, D. Veyer, A.M. Savoye, J. Berthet, C. Caux, F. Lecuru, B. Dubois* and S. Bétrian*
  GINECO window-of-opportunity COLIBRI study of neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma. *Co-senior authors.
  Nature Communications, (2026) 17(1): 922.
• O. Le Saux, R. Sabatier, I. Treilleux, L.I. Renaud, P.E. Brachet, A. Martinez, J.S. Frenel, C Abdeddaim, J. Berthet, S. Barrin, A. Colombe-Vermorel, L. Odeyer, A. Lainé, C. Caux, B. Dubois* and I. Ray-Coquard*
  Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy. *Co-senior authors.
  Ther Adv Med Oncol, (2025) Vol. 17: 1–14.
• PA Cassier, MJ Borad, S Sharma, B Dubois, C Caux, F Okano, DD Von Hoff and JY Blay
  Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors.
  Cancer Res Commun. (2025) 5(7):1119-1128.
• L Collet, JC Noël, X Catteau, M Ardin, J Berthet, S Ghamry-Barrin, I Treilleux, L Bengrine Lefevre, M Martinez, F Rothé, C Sotiriou, C Caux, B Dubois, I Ray-Coquard and O Le Saux
  Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
  ESMO Open, (2025) Jun;10(6):105104.
• L. Collet, M. Ardin, D. Venet, J. Berthet, S. Ghamry-Barrin, I. Treilleux, J.C. Noel, M. Leheurteur, J. Meunier, L. Bengrine-Lefevre, M.Martinez, F. Priou, F. Selle, P.A. Just, G. Bataillon, F. Rothé, C. Sotiriou, C. Caux, B. Dubois, I. Ray-Coquard and O. Le Saux
  Unravelling tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial.
  Clin Cancer Res, (2025) 31(15):3317-3331.
• Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B*, Ray-Coquard I*.
  Immunogenomic profiling of the randomized NeoPembrOv clinical trial 2 reveals regulatory T cells and the VEGFR2 angiogenic axis as promising 3 actionable targets to overcome immunoresistance of high-grade ovarian 4 carcinomas. *Co-senior authors.
  Nat Commun (2024) 15(1):5932.
• Dalle S*, Verronese E*, N’Kodia A*, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M¹, Bendriss-Vermare N, Dubois B, Caux C^¥, Ménétrier-Caux C^¥
  Modulation of Blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. ^¥Co-senior author.
  OncoImmunology (2024)13(1):2372118.
• Voissière A†, Gomez-Roca C†, Chabaud S†, Rodriguez C†, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C†, Bendriss-Vermare N†, Cassier PA† († co-first or co-last author).
  Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling which may antagonize the effect of durvalumab in patients with advanced cancer- a phase 1 study.
  Science Translational Medicine (2024) 16(731):eadd1834.
• Di Roio A, Hubert M, Besson L, Bossennec M, Rodriguez C, Grinberg-Bleyer Y, Lalle G, Moudombi L, Schneider R, Degletagne C, Treilleux I, Campbell D, Metzger S, Duhen T, Tredan O, Caux C*, Ménétrier-Caux C*.
  MDR1-expressing CD4+ T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response.
  J Immunother Cancer. (2023) 11(11):e007733. doi: 10.1136/jitc-2023-007733.
• Mery B*, Ménétrier-Caux C*, Montané L, Heudel PE, Ray-Coquard I, Bachelot T, Derbel O, Augereau P, Treilleux I, Berthet J, Nkodia A, Bardin-Dit-Courageot C, Attignon V, Ferrari A, Garin G, Pérol D, Caux C, Dubois B^¥ and Trédan O^¥.
  Pembrolizumab in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide: a clinical and translational prospective study. (*Co-first author, ^¥Co-senior authors).
  Breast Cancer: Targets and Therapy (2023) 15:311-325.
• Gouez M, Pérol O, Pérol M, Caux C, Ménétrier-Caux C, Villard M, Walzer T, Delrieu L, Saintigny P, Marijnen P, Pialoux V, Fervers B.
  The effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: Protocol for the ERICA feasibility trial.
  BMJ Open (2022) 12(4):e056819. doi: 10.1136/bmjopen-2021-056819.
• Dufresne A, Lesluyes T, Ménétrier-Caux C, Brahmi M, Darbo E, Toulmonde M, Italiano A, Mir O, Le Cesne A, Le Guellec S, Valentin T, Chevreau C, Bonvalot S, Penel N, Coindre JM, Caux C, Blay JY, Chibon F.
  Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GIST.
  OncoImmunology (2020) 9:1, 1792036,
• Ménétrier-Caux C, Ray-Coquard I, Blay JY, Caux C.
  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
  J Immunother Cancer (2019) Mar 28;7(1):85.
• Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N’Kodia A, Bardin C, Rigal C, Pérol D, Caux C*, Ménétrier-Caux C* ( *co-last authorship)
  Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.
  OncoImmunology (2015) 5(3):e1100791.
• Trédan O≠, Ménétrier-Caux C≠, Ray-Coquard I≠, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot, Rigal C, N’Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY*, Caux C* (≠co-first authorship, * co-last authorship).
  ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
  Annals of Oncology (2015) 26(7):1353-62.
• Mathieu AL, Verronese E, Rice GI,Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD,  Butte M, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot M, Balme B,Viel S, Bienvenu J, Cochat P, van Der Burg M, Caux C, Kemp H, Rouvet I, Malcus C, Crow YJ,Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T and Belot A.
  PRKDC mutations associated with immunodeficiency, granuloma and AIRE-dependent auto-immunity.
  J Allergy Clin Immunol. (2015) 135(6):1578-88.e5.
• Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F.
  Spontaneous regression of breast cancer after biopsy. About two cases.
  Gynecol Obstet Fertil. (2014) 42:269-72
• Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson  G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY. CD4 lymphopenia to identify end-of-life metastatic cancer patients.
  Eur J Cancer (2013) 49:1080-1089.
• Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C and Ménétrier-Caux C.
  Patients with metastatic breast cancer leading to CD4+ T cell Lymphopenia have poor outcome.
  Eur J Cancer (2013) 49:1673-1682.
• Manuel M, Tredan O, Bachelot T, Clapissson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY and Ménétrier-Caux C.
  Lymphopenia Combined with low TCR Diversity (divpenia) predicts poor Overall Survival in Metastatic Breast Cancer Patient. OncoImmunology (2012) 1:433-442.
• Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O, Goddard-Leon S, Pin JJ, Mignotte H, Barthelemy-Dubois C, Caux C, Lebecque S, Blay JY.
  Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.
  BMC Cancer (2011) 11:213-223.
• Labidi-Galy SI, Ménétrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P,  Blay JY and Ghesquières H.
  Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival.
  Annals Hematol. (2010) 89:25-33.
• Evrard S, Ménétrier-Caux C, Biota C, Neaud V, Mathoulin-Pélissier S, Blay JY, Rosenbaum J.
  Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases.
  Gastroenterol Clin Biol. (2007) 31, 141-5.
• Bachelot T, Ratel D, Ménétrier-Caux C, Wion D, Blay J-Y and Berger F.
  Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome.
  Br. J. Cancer (2006) 94, 1066-70.
• Borg C.*, Ray-Coquard I.*, Philip I., Clapisson G., Bendriss-Vermare N., Ménétrier-Caux C., Sebban C., Biron P., J-Y. Blay.
  CD4 lymphopenia as risk factor for febrile neutropenia and early death after polychemotherapy in HIV negative cancer patients. (*contribution égale)
  Cancer (2004) 101(11), 2675-80.
• Négrier S, Perol D, Ménétrier-Caux C, Escudier B, Pailardy M, Ravaud A, Douilard JY, Chevreau C, Lasset C and Blay JY.
  Serum interleukin-6, interleukin-10 and vascular endothelial growth factor in metastatic renal cell carcinoma. Prognostic value of interleukin-6.
  J Clin Oncol (2004) 22(12), 2371-8.
• Bachelot T, Ray-Coquard I, Ménétrier-Caux C, Rastkha M, Duc A and Blay JY.
  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
  Br. J. Cancer (2003) 88, 1721 – 6